PharmaNet system dramatically reduced inappropriate prescriptions of potentially addictive drugs

September 4, 2012

A centralized prescription network providing real-time information to pharmacists in British Columbia, Canada, resulted in dramatic reductions in inappropriate prescriptions for opioid analgesics and benzodiazepines, widely used and potentially addictive drugs. The findings are reported in a study in CMAJ (Canadian Medical Association Journal).

The study found that PharmaNet, a real-time prescription system implemented in BC pharmacies in July 1995, reduced potentially inappropriate prescriptions for opioids and benzodiazepines in two groups of patients—those on social assistance and seniors. The reductions ranged from about one-third (33%) to one-half (49%) depending on the drug and patient group.

"Our study demonstrates that a system like PharmaNet can help reduce the potentially inappropriate prescribing of medications that are prone to misuse," said lead author Colin Dormuth of the Therapeutics Initiative at the University of British Columbia. "In the five-year period of our study, the reduction in inappropriate refills was dramatic and sustained after the implementation of PharmaNet."

The PharmaNet system allows BC pharmacists to view the most recent 14 months of a patient's medication use regardless of which physician prescribed the drugs or which pharmacy dispensed them. The system enables pharmacists to identify potentially harmful drug interactions, accidental duplications in therapy or potential prescription .

Researchers tracked "potentially inappropriate" prescriptions for opioids and benzodiazepines in BC, defined as a second prescription for the same drug issued by a different doctor and a different pharmacy within 7 days of a previous prescription for at least 30 tablets.

Benzodiazepines and are that are prone to misuse and addiction in some patients. Benzodiazepines include sedatives and anti-anxiety drugs such as diazepam, lorazepam and others, whereas are taken for pain relief and include morphine, codeine, oxycodone and other drugs.

Most provinces have now adopted either a system allowing the to view a patient's up-to-date medication history at the time of dispensing a medication or a real-time monitoring program specifically aimed at monitoring prescription drugs prone to misuse. Ontario adopted the latter approach in establishing its Narcotics Monitoring System earlier this year.

"Centralized drug information systems and monitoring programs are critical to help ensure these medications are used appropriately," observes coauthor David Juurlink, Head of Clinical Pharmacology and Toxicology at Toronto's Sunnybrook Health Sciences Centre and a scientist at the Institute for Clinical and Evaluative Sciences (ICES).

The study covered the period from Jan. 1, 1993 to Dec. 31, 1997—the 5-year period flanking the program's implementation. Because comprehensive data was available for people aged 65 years and over and patients receiving social assistance, the study focused on these two groups of patients.

Explore further: Harmful patterns of painkiller prescriptions seen among methadone patients

More information: www.cmaj.ca/lookup/doi/10.1503/cmaj.120465

Related Stories

Harmful patterns of painkiller prescriptions seen among methadone patients

November 28, 2011
A new study has shown harmful prescription patterns of powerful painkillers among a substantial number of Ontario patients who received methadone therapy to treat their opioid addiction.

Opioids linked to higher risk of pneumonia in older adults

September 22, 2011
Opioids -- a class of medicines commonly given for pain -- were associated with a higher risk of pneumonia in a study of 3,061 adults, aged 65 to 94, e-published in advance of publication in the Journal of the American Geriatrics ...

Black patients more likely to be monitored for prescription drug abuse

May 10, 2011
(Medical Xpress) -- Despite studies that show that whites are more likely than blacks to misuse prescription pain medications, a new study reveals that blacks are significantly more likely than whites to be checked for potential ...

Study shows pharmacies' software systems miss potentially dangerous interactions

May 17, 2011
A study conducted at the University of Arizona College of Pharmacy found that only 28 percent of pharmacies' clinical decision support software systems – the computer programs that are in place to alert pharmacists to ...

Drexel study: Misuse of pain medication is pathway to high-risk behaviors

July 22, 2011
A new study by researchers at Drexel University's School of Public Health suggests that abuse of prescription painkillers may be an important gateway to the use of injected drugs such as heroin, among people with a history ...

Recommended for you

Cancer drugs' high prices not justified by cost of development, study contends

September 12, 2017
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs.

Non-psychotropic cannabinoids show promise for pain relief

September 4, 2017
Some cancers love bone. They thrive in its nutrient-rich environment while gnawing away at the very substrate that sustains them, all the while releasing inflammatory substances that cause pain—pain so severe that opioids ...

Fentanyl drives rise in opioid-linked deaths in U.S.

August 31, 2017
(HealthDay)—Fentanyl, a synthetic narcotic, is a key player in America's continuing epidemic of opioid-related overdose deaths, two new studies report.

Eating triggers endorphin release in the brain

August 28, 2017
Finnish researchers have revealed how eating stimulates brain's endogenous opioid system to signal pleasure and satiety.

Cholesterol-lowering drugs may fight infectious disease

August 21, 2017
That statin you've been taking to lower your risk of heart attack or stroke may one day pull double duty, providing protection against a whole host of infectious diseases, including typhoid fever, chlamydia, and malaria.

Data revealed under FOI shows benefits of multiple sclerosis drug currently blocked by regulators

August 17, 2017
A drug that is blocked by the EU regulatory system has now been found to improve the quality of life of people with multiple sclerosis (MS), according to a study by Queen Mary University of London (QMUL).

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.